I’m no expert, but it seems to me at a time when the risks of blood clotting have been thrust into the public eye, it could hardly come at a better time:
Phase 2 trial showed NEXTSTELLISTM to have a lower effect than other DRSP containing oral contraceptives on certain markers of coagulation (blood clotting)
My understanding is the chance of blood clotting from the AstraZeneca Covid vaccine is negligible compared to getting hit by lightning, but it does appear to be a more significant issue with contraceptives and now there is a personal choice that can be made to mitigate that risk.
so, what’s this worth to the MYX bottom line annually for the first 20 years?
Ann: FDA approval of novel oral contraceptive NEXTSTELLIS, page-14
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.83 |
Change
-0.200(4.96%) |
Mkt cap ! $325.8M | |||
| Open | High | Low | Value | Volume |
| $4.00 | $4.00 | $3.78 | $852.5K | 220.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1750 | $3.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.85 | 578 | 1 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| MYX (ASX) Chart |